<DOC>
	<DOCNO>NCT01372085</DOCNO>
	<brief_summary>This single-centre , placebo-controlled , two-part study healthy subject . Part A single dose , single period , placebo-controlled pilot study explore safety , tolerability , absorption pharmacodynamic ( effect drug biological marker-pS6 level skin biopsy ) single dose 25 mg LY2584702 Reference formulation ( RF ) . Part B single dose , placebo-controlled , 4-period crossover study primarily evaluate absorption Test Formulation ( TF ) comparison ( RF ) LY2584702 .</brief_summary>
	<brief_title>Single Dose Study Healthy Volunteers Investigate Safety Absorption LY2584702</brief_title>
	<detailed_description />
	<criteria>Male subject : Agree use reliable method birth control study least 1 month follow last dose study drug Female subject : Women childbearing potential due surgical sterilization ( hysterectomy bilateral oophorectomy tubal ligation ) menopause . Women intact uterus deem postmenopausal great equal 45 year old , take hormone oral contraceptive within last year , cessation menses least 1 year , 6 12 month amenorrhea folliclestimulating hormone ( FSH ) level consistent postmenopausal state . screen body mass index 18.5 32.0 kg/m^2 , inclusive clinical laboratory test result within normal range population investigator site , abnormality deem clinically insignificant investigator . In particular , subject normal near normal screen liver test discretion investigator normal blood pressure pulse rate ( supine ) screening , minor deviation judge acceptable investigator venous access sufficient allow blood sample per protocol reliable willing make available duration study willing follow study procedure give write informed consent approve Lilly ethical review board ( ERB ) govern site currently enrol , complete discontinue within last 30 day , clinical trial involve investigational product investigational product use study ; concurrently enrol type medical research judge scientifically medically compatible study . Subjects participate Part A study may participate Part B study first dose Part B &gt; 30 day dose LY2584702 placebo Part A. know allergy LY2584702 , related compound abnormality 12lead ECG ( include limit Bazett 's correct QT [ QTcB ] interval &gt; 450 msec men &gt; 470 msec woman ) history within last 2 year presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data history drug alcohol abuse , regularly use know drug abuse show evidence human immunodeficiency virus infection and/or positive human immunodeficiency virus ( HIV ) antibodies show evidence hepatitis B and/or positive hepatitis B surface antigen intend use overthecounter prescription medication within 14 day prior dose study use herbal supplement , grapefruit juice , grapefruit , Seville orange juice , Seville oranges , Starfruit within 7 day prior study dose intend use study donate blood 450 mL within last 3 month average weekly alcohol intake exceed 21 unit per week ( male ) 14 unit per week ( female ) , unwilling stop alcohol consumption prior dose completion study period ( 1 unit = 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) Applicable Part A : â€¢ know allergy lignocaine , adrenaline , tetracycline , related compound , use skin biopsy procedure</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>